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Abstract
Objective—It had been previously shown that patients who receive neoadjuvant systemic therapy 
(NST) are more likely to undergo breast-conserving therapy (BCT) than those who have primary 
surgery. However, the frequency with which patients who are not BCT-eligible prior to NST 
convert to BCT-eligible with treatment is unknown. To document this conversion rate in a subset 
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of patients expected to have a high clinical response rate to NST, we studied surgical assessment 
and management of patients enrolled on a randomized neoadjuvant trial for stage II–III HER2-
positive breast cancer (HER2 + BC)(CALGB 40601).
Methods—The treating surgeon assessed BCT candidacy based on clinico-radiographic criteria 
both before and after NST. Definitive breast surgical management was at surgeon and patient 
discretion. We sought to determine (1) the conversion rate from BCT-ineligible to BCT-eligible (2) 
the percentage of BCT-eligible patients who chose breast conservation, and (3) the rate of 
successful BCT. We also evaluated surgeon-determined factors for BCT-ineligibility and the 
correlation between BCT eligibility and pathologic complete response (pCR).
Results—Of 292 patients with pre- and post-NST surgical assessments, 59 % were non-BCT 
candidates at baseline. Of the 43 % of these patients who converted with NST, 67 % opted for 
BCT, with an 80 % success rate. NST increased the BCT-eligible rate from 41 to 64 %. Common 
factors cited for BCT-ineligibility prior to NST including tumor size (56 %) and probable poor 
cosmetic outcome (26 %) were reduced by 67 and 75 %, respectively, with treatment, while 
multicentricity, the second most common factor (33 %), fell by only 16 %. Since 23 % of the BCT-
eligible patients chose mastectomy, BCT was the final surgical procedure in just 40 % of the 
patients. Patients considered BCT-eligible both at baseline and after NST had a pCR rate of 55 %, 
while patients who were BCT-ineligible prior to NST had the same pCR rate (44 %) whether they 
converted to BCT-eligible or not.
Conclusions—Many patients with HER2 + BC deemed ineligible for BCT at baseline can be 
converted to BCT-eligible with NST; excluding patients with multicentric disease substantially 
increases that percentage. In converted patients who opt for BCT, the success rate is similar to that 
of patients considered BCT-eligible at baseline. Whether a BCT-ineligible patient converts to BCT 
eligibility or not does not appear to affect the likelihood of achieving a pCR. Despite the efficacy 
of NST in this patient cohort, only 40 % of patients had successful BCT; further research into why 
BCT-eligible patients often opt for mastectomy is needed.
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Introduction
Historically, neoadjuvant systemic therapy (NST) was used to convert patients with 
inoperable breast cancer to operable. More recently, NST has been utilized to allow some 
patients with stage II–III breast cancer for whom mastectomy is indicated to undergo breast-
conserving therapy (BCT) by down-staging the volume of disease [1–4]. The intent to down-
stage the primary tumor is often the rationale given to administer systemic therapy in the 
neoadjuvant rather than the adjuvant setting, especially in patients with aggressive breast 
cancer subtypes such as triple-negative breast cancer (TNBC) and human epidermal growth 
factor receptor-2-positive breast cancer (HER2 + BC). BCT after NST has equivalent 
locoregional recurrence rates and survival compared to BCT performed prior to systemic 
adjuvant therapy, and is therefore a safe option [1–4].
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While some studies that compared the same regimens used as either neoadjuvant or adjuvant 
therapy have demonstrated higher BCT rates in the NST arm, these reports were based on 
retrospective analyses with now outdated treatment regimens. Little data exist from large 
trials to allow estimation of the success rate for converting BCT-ineligible patients to BCT-
eligible, nor do we have prospective data as to how often patients converted to BCT-eligible 
nonetheless chose mastectomy, the likelihood of achieving negative margins when BCT is 
attempted and what proportion of converted patients achieved a pathologic complete 
response (pCR). Most previously published neoadjuvant studies did not examine the reasons 
for surgical-decision making for BCT or mastectomy. Thus, the impact of NST on surgical 
options remains unclear and a better understanding of these topics is the purpose of the study 
described here. We have previously published the prospective surgical companion trial for 
CALGB 40603, on which patients with triple-negative breast cancer (TNBC) received NST, 
which utilized identical pre- and post-surgical evaluations [5].
CALGB 40601 was a randomized phase III trial that compared lapatinib (L) or the 
combination of L and trastuzumab (T) to T given in combination with neoadjuvant wP 
(weekly paclitaxel) in stage II–III HER2 + BC [6]. The primary clinical endpoint was pCR, 
defined as the absence of residual invasive disease in the breast. CALGB 40601 incorporated 
a practice-oriented surgical study whose primary surgical endpoint was to assess the 
percentage of patients who underwent BCT. In addition, the treating surgeon assessed 
eligibility for BCT both before and after completion of NST and recorded reasons for non-
candidacy of BCT. This is a planned analysis of the trial to assess BCT conversion rates and 
final surgical outcomes.
Methods
Patient eligibility
Patients with stage II or III HER2 + BC with operable, biopsy confirmed, previously 
untreated, non-inflammatory disease were eligible. HER2 positivity was defined as IHC 3+ 
or fluorescent-in situ-hybridization (FISH) amplified (ratio ≥ 2.0).
Study procedures
Baseline breast imaging, which included mammography with or without focused breast 
ultrasound, was required for all patients. Magnetic resonance imaging was recommended but 
not required. Based upon physical exam, tumor size relative to native breast size, and review 
of breast imaging studies, the treating breast surgeon assessed eligibility for BCT both 
before treatment initiation and at the end of NST, and documented all reasons for BCT 
ineligibility at those time points. Successful BCT was defined as no ink on tumor of a 
lumpectomy specimen. Mastectomy could be performed either as primary surgery at patient 
or physician discretion or following unsuccessful attempted BCT. Surgical therapy on 
CALGB 40601 occurred within 6 weeks of the last dose of wP. Genetic testing for BRCA 
mutations was not required for the study. The treatment arms described in the introduction 
are shown in Fig. 1.
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Pathologic response was determined locally, with pCR in the breast only defined as the 
absence of residual invasive disease with or without residual ductal carcinoma in situ (DCIS) 
(yp T0/is); an additional secondary analysis was done for pCR defined as the absence of 
both invasive disease and ductal carcinoma in situ (yp T0).
Data collection and analysis
The primary outcome variable of interest was conversion from pre-NST BCT ineligibility to 
post-NST BCT eligibility. Eligibility for BCT (both pre and post) was scored as yes/no. The 
conversion rate to BCT candidacy was calculated as the number of patients whose eligibility 
for BCT changed from ineligible pre-NST to eligible post-NST, divided by the number 
identified as ineligible pre-NST. Additional items of interest were as follows: (1) proportion 
of patients who were BCT candidates both before and after NST; (2) proportion of BCT 
candidates in whom BCT was attempted; (3) BCT success rate; (4) pCR rates by BCT 
eligibility pre- and post-NST; and (5) final surgical procedure. Proportions and their 
respective 95 % confidence intervals (CI) were calculated using exact binomial methods. To 
test the change from pre- to post-NST eligibility, the McNemar’s test was used. 
Comparisons of proportions across groups were examined with the Chi square test. To 
model the relation of several baseline clinicopathologic variables to BCT candidacy 
following NST, logistic regression was used in which post-NST BCT candidacy was the 
dependent variable. Independent covariables were patient age, tumor grade, and size, 
whether or not NST was terminated early, and pre-NST BCT candidacy. The observed effect 
of each independent variable was assessed with its corresponding Wald Chi square. Adjusted 
odds ratios (OR) and 95 % confidence intervals were taken from the multivariate logistic 
model. Analyses used an intent-to-treat approach that included all patients who began 
protocol NST, analyzed according to their randomized assignment.
Data were collected and stored at the CALGB Statistics and Data Center (Durham, NC) with 
quality ensured through data review performed by the Data Center, the study chairperson 
(LAC), and surgical co-chairs (MG and DWO). Statistical analyses were performed by 
CALGB statisticians using SAS 9.2 (Cary, NC). The data cutoff for this report was January 
2015.
Results
The trial accrued a total of 305 patients between 2009 and 2012. A total of 292 began 
protocol therapy, and are included in current analyses. Results for the primary endpoint 
(pCR) have been previously published [6]. Patient and tumor characteristics are displayed in 
Table 1. Two-thirds of patients (68 %) were clinical stage II and 32 % were clinical stage III. 
The median age was 49; 59 % were premenopausal; 66 % had high-grade disease, and 94 % 
had ductal histology.
Prior to NST, 121 (41 %) patients were considered eligible for BCT; of these, 113 (93 %) 
remained eligible after NST and 94 (83 %) underwent BCT, which was successful in 79 
(84 %) (Fig. 2). Of the 171 (59 %) patients who were considered ineligible for BCT pre-
NST, 73 (43 %) were converted to eligible for BCT after treatment. Of these, BCT was 
attempted in 49 (67 %) and was successful in 39 (80 %) (Fig. 2). Overall, there was a 
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significant increase in the incidence of surgeon-determined BCT eligibility from 41 % 
(121/292) prior to NST to 64 % (186/292) after NST (p < 0.001).
Of all patients who were eligible for BCT, 77 % (143/186) attempted BCT with an 83 % 
(118/143) success rate, while the remaining 23 % (43/186) opted to proceed to mastectomy. 
Final surgical management was BCT in 118 (40 %) patients and mastectomy in 174 (60 %) 
patients, including the 25 in whom BCT was unsuccessful.
Of the 171 patients who were judged not to be candidates for BCT prior to NST, the primary 
reasons identified by the breast surgeon (more than one reason may apply) were as follows: 
tumor too large [95 (56 %)], multicentric disease [56 (33 %)], probable poor cosmetic 
outcome [44 (26 %)], and diffuse suspicious microcalcifications [20 (12 %)]. Among the 
106 patients deemed not to be candidates for BCT after NST, the primary factors cited were 
as follows: multicentric disease [47 (44 %)], tumor too large [31(29 %)], diffuse suspicious 
microcalcifications [17(16 %)], and probable poor cosmetic outcome [11 (10 %)]. (Table 2).
Figure 3 illustrates the incidence of pathologic complete response according to breast 
conservation candidacy. Of the 113 patients who were candidates for BCT both before and 
after NST, the pCR rate (ypT0/is) was 55 % (95 % CI 46–64 %). In patients deemed BCT-
ineligible before NST, this pCR rate was identical (44 %) among the 73 who converted to 
BCT-eligible and the 98 who remained BCT-ineligible after NST. (p = 0.13), and was not 
altered if the more stringent definition of pCR requiring eradication of in situ as well as 
invasive disease from the breast (ypT0) is used. After adjusting for standard baseline 
variables of clinicopathologic importance, BCT candidacy prior to NST was the strongest 
predictor of candidacy post-NST (OR 17.88, 95 % CI 8.03–39.82, p < 0.0001).
Discussion
In this planned analysis of a prospective surgical sub-study embedded within a large, 
randomized NST trial, we demonstrate that a substantial fraction (43 %) of patients with 
HER2 + BC deemed ineligible for BCT at presentation can be successfully converted to 
BCT-eligible with NST. While these patients were somewhat less likely to an attempt at 
BCT than patients who were BCT-eligible both at baseline and after NST (67 vs. 83 %), they 
did their success rate was essentially identical (80 vs. 84 %). In HER2 + BC patients 
considered BCT-ineligible at baseline due to tumor size or probable poor cosmetic outcome, 
NST was very likely (67 and 75 % respectively) to eliminate that impediment, whereas in 
patients with multicentric disease NST was unlikely (16 %) to expand their surgical options. 
Were we to exclude patients with multicentric disease, currently considered as a 
contraindication to BCT, from our analysis, the conversion rate would doubtless have been 
much higher. Similarly, because the extent of diffuse microcalcifications, often a marker of 
DCIS, is typically not affected by NST, the frequency with which this was cited as a 
criterion for non-candidacy for BCT remained stable from prior to (n = 20) to after (n = 17) 
NST.
In addition to the 36 % of patients who remained BCT-ineligible (for whatever reason) after 
NST, and the 17 % of BCT-eligible patients whose attempted BCT failed to achieve negative 
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margins, leading to subsequent mastectomy, a substantial fraction (23 %) of BCT-eligible 
patients opted for mastectomy as their primary surgery; as a result, the overall BCT rate was 
just 40 %. One of the limitations of our study was the failure to collect surgeon and patient 
reasons for foregoing BCT in eligible patients. Many factors probably weigh into this 
decision making, including widespread availability of BRCA mutation testing, identifying 
mutation carriers in whom bilateral mastectomy is considered by many the standard of care, 
but also the trend towards higher mastectomy and contralateral prophylactic mastectomy 
rates in BRCA-unknown and even BRCA-negative women seen in the US over the past 
decade, despite the absence of evidence that mastectomy results in improved survival in non-
BRCA carriers.
Whether being able to identify patients who were BCT-ineligible at baseline who were 
highly likely to have achieved pCR with NST would reduce the mastectomy rate in 
unknown. However, in our patient population, the inability of conversion from BCT-
ineligible to BCT-eligible to predict a greater likelihood of having achieved a pCR limits our 
ability to reassure the patient about the efficacy of the NST in eradicating disease in the 
breast, and neither clinical complete response nor resolution of abnormalities on imaging 
studies with NST has been shown to correlate strongly with achievement of pCR. Nor was 
BCT-eligibility at baseline or conversion from ineligibility to eligibility with NST 
substantially more likely to correlate with the more stringent ypTN0 definition of pCR.
Results of multivariable analysis indicated that planned BCT prior to NST was the strongest 
predictor of BCT eligibility post-NST, mirroring another neoadjuvant trial in HER2 + BC 
[8].
The results presented here of CALGB 40601 are remarkably similar to those of CALGB 
40603, an NST trial for TNBC [5]. The conversion from BCT-ineligible to BCT-eligible 
was, respectively, 43 vs. 42 %; the patients remaining candidates for BCT was 93 vs. 90 %; 
the final BCT rate was 40 vs. 47 %; and the overall pCR was 48 vs. 54 %. Surgical practice 
patterns for these two NST trials run by the same cooperative group which incorporate 
academic and community centers showed very similar surgical treatment patterns and 
outcomes for women with TNBC and HER2 + BC.
The incidence of BCT success when attempted was high at 83 %, while the incidence of 
BCT as the final surgical procedure was 40 %. The latter needs to be viewed in the context 
of two large, recent neoadjuvant trials that involved women with HER2 + BC. One was Neo-
ALLTO, a European phase III neoadjuvant trial of women with HER2 + BC; the other was 
GeparSixto, a European neoadjuvant trial for HER2 + BC and TNBC conducted by the 
German Breast Group (GBG) [7, 8]. Neo-ALLTO reported a similar BCT rate of 44 %, but 
noted that a smaller proportion of patients treated in ‘developing countries’ underwent BCT 
compared to other countries (32 vs. 53 %). This difference was theorized to be due to a lack 
of optimal radiotherapy or the absence of a multidisciplinary breast center at participating 
sites in those countries [7]. In contrast, despite pCR rates similar to those achieved in our 
trials, in GeparSixto the GBG achieved a BCT rate of nearly 75 %, though the addition of 
carboplatin to the control neoadjuvant regimen did not raise the BCT rate despite a 
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significant increase in the pCR rate. To what extent these differences in BCT rates are driven 
by medical versus cultural or economic reasons need to be explored in future NST trials.
When we turn to the neoadjuvant setting to study novel agents, the question remains whether 
higher pCR rates will be accompanied by a concomitant increase in BCTs. Despite pCR 
rates of 38–55 %, a sizable increase in BCT eligibility following NST and a high likelihood 
of success for those who chose BCT, our final BCT rate was only 40 %.
This incongruity between higher clinical and pathologic response rates and the persistence 
of low overall BCT rates is partially explained by the substantial number of BCT-eligible 
patients, regardless of whether they were always candidates for BCT or converted to 
candidates with NST, who choose not to attempt breast conservation. Instead, these patients 
and their surgeons opted for mastectomy as their definitive oncologic surgery during the first 
surgical procedure irrespective of the clinico-radiographic response to NST. Patient and 
surgeon perceptions are complex and layered, with respect to the risks of an in-breast 
recurrence or development of a secondary primary breast cancer, and likely played a role in 
many of these decisions [9–11]. These findings underscore the importance of all members of 
the breast cancer care team to convey to patients an accurate assessment of their risk of loco-
regional recurrence and second primary cancers, as well as to discuss surgical risks and 
likely cosmetic outcomes associated with the various surgical options so that patients can 
make informed decisions regarding their local management. Surgical oncologists need to 
incorporate appropriate breast imaging, before and after NST, to improve their assessment of 
treatment response so that suitable patients can be offered and encouraged to attempt BCT. 
This incongruity is seen by the over 40 % of patients deemed not candidates for BCT found 
to have a pCR on final pathology.
Our study has several limitations including the lack of information on genetic propensity to 
breast cancer that could influence surgical decisions, although it is likely to be of limited 
impact in HER2 + BC. We did not collect data on factors such as need for additional 
imaging and biopsy, fear and risk perceptions of HER2 breast cancer subtypes for 
recurrence, and patient and surgical biases that could play a role in decision-making 
regarding local therapy [12–14].
In conclusion, we present results from a large modern era NST of HER2 + BC. Despite high 
rates of pCR and reduction in factors that would preclude BCT, 60 % of patients underwent 
mastectomy. Our surgical results for HER2 + BC are remarkably similar to our results for 
TNBC, CALGB 40603. Future trials to address patient- and surgeon-specific factors should 
be designed in a prospective fashion to tailor recommendations for receipt of BCT [15]. If a 
major goal of NST is to actually increase BCT rates, while we have demonstrated the ability 
of NST to increase BCT eligibility in this patient population, the results are disappointing. 
Our numbers of patients undergoing BCT are lower than decades past when NST regimens 
had more limited efficacy in terms of reducing in breast tumor burden. These results reflect 
the need to identify the factors that influence our patients’ decision-making process, and to 
provide them with information to reduce selection of unnecessarily aggressive treatment 
options. While mastectomy is not the wrong option for breast cancer local therapy, we 
believe that it is being used far too frequently in patients who are good candidates for BCT 
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after NST and have no specific indications for (such as a documented BRCA mutation) or 
contraindications to BCT, given advances in NST, especially in patient populations such as 
ours (HER2 + BC). Our work highlights the continued trend in the surgical overtreatment of 
breast cancer, despite ample research demonstrating the equivalence of BCT and 
mastectomy in clinical outcomes.
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Fig. 1. 
C40601 Schema T weekly paclitaxel; H trastuzumab; L lapatinib.
*Excluding clinical T4d tumors
Golshan et al. Page 10
Breast Cancer Res Treat. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 2. 
Surgical outcomes in c40601
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Fig. 3. 
Surgical outcomes and pCR in c40601
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Table 1
Patient and tumor baseline characteristics
Characteristic N (%)
Total, n (%) 292 (100)
Stratification
 Clinical stage, n (%)
  II 200 (68)
  III 92 (32)
Baseline variables
 Patient age, n (%)
  20–29 6 (2)
  30–39 51 (17)
  40–49 100 (34)
  50–59 82 (28)
  60–69 43 (15)
  70–79 10 (3)
 Median age (IQR) 49 (41–56)
 Minimum age, maximum age 24–75
 Menopausal status, n (%)
  Premenopausal 173 (59)
  Postmenopausal 119 (41)
 Clinical T stage (by physical exam), n (%)
  T0 3 (1)
  T1 16 (5)
  T2 178 (61)
  T3 75 (26)
  T4 10 (3)
  Missing/unknown 10 (3)
 Tumor grade, n (%)
  Low 10 (3)
  Intermediate 84 (29)
  High 193 (66)
  Missing/unknown 5 (2)
 Tumor histology n (%)
  Ductal 274 (94)
  Lobular 4 (1)
  Mixed ductal and lobular 0 (0)
  Invasive, NOS 7 (2)
  Other 6 (2)
  Missing/unknown 1 (<1)
Breast Cancer Res Treat. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Golshan et al. Page 14
Table 2
Reasons for BCT non-candidacy
Characteristic N (%)
Pre-NST (non-candidate)
 Total 171 (100)
 Tumor too large 95 (56)
 Probable poor cosmetic outcome 44 (26)
 Contraindication to RT 1 (1)
 Diffuse suspicious microcalcifications 20 (12)
 Multicentric disease 56 (33)
Post-NST (non-candidate) 106 (100)
 Total 106 (100)
 Tumor too large 31 (29)
 Probable poor cosmetic outcome 11 (10)
 Contraindication to RT 1 (1)
 Diffuse suspicious microcalcifications 17 (16)
 Multicentric disease 47 (44)
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